The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.
This technology includes the use of Interferon-gamma (IFN-y) as a therapeutic agent to inhibit the proliferation and migration of human retinal pigment epithelial (RPE) cells, which is crucial in treating proliferative eye diseases such as age-related macular degeneration and proliferative vitreoretinopathy. The problem at hand is that abnormal RPE cell behavior is linked to severe ocular diseases that can lead to vision loss, affecting millions of individuals, particularly the elderly. The inventors have discovered that IFN-y can significantly reduce this abnormal cell activity, providing a potential treatment pathway for these debilitating conditions.
The technical solution involves intraocular injections of IFN-y, which have shown promise in halting excessive RPE proliferation and migration, thereby preventing the formation of abnormal tissues in the eye. This technology is important because it addresses a significant unmet medical need in ophthalmology, offering a novel approach to managing diseases that currently have limited treatment options. By targeting the underlying cellular mechanisms, this therapy could improve patient outcomes and reduce the burden of vision loss associated with these conditions.
The licensing opportunity for this technology is aimed at pharmaceutical companies and research institutions interested in developing new treatments for ocular diseases. The inventors are seeking partners for co-development and commercialization, emphasizing the potential for collaborative efforts to bring this innovative therapy to market. This collaboration could involve further clinical trials and research to validate the efficacy and safety of IFN-y in treating proliferative eye diseases.